MDxHealth, Inc.'s Confirmmdx® For Prostate Cancer Epigenetic Test Correctly Identifies Prostate Cancer Missed In Five Previous Biopsies
IRVINE, Calif. and HERSTAL, Belgium, Feb. 12, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx® for Prostate Cancer test was used as part of an multidisciplinary approach to successfully confirm prostate cancer diagnosis missed by five previous biopsies. The case study of a 63-year old man was published online in The Journal of OncoPathology (La Rosa FG, Jones C, Arangua P, Crawford ED & Van Neste L (2013). Finding Occult Prostatic Cancer: The Value of Transperineal Mapping Biopsies and Epigenetic Assays http://www.ingentaconnect.com/content/oc/tjop/preprints/content-tjop100078) by researchers from the University of Colorado (USA) and Maastricht University Medical Center (Netherlands).
Help employers find you! Check out all the jobs and post your resume.